Trastuzumab biosimilar - DM Bio

Drug Profile

Trastuzumab biosimilar - DM Bio

Alternative Names: DA-3111; DMB-3111

Latest Information Update: 30 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dong-A Pharmaceutical
  • Developer DM Bio
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action ERBB 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Breast cancer; Gastric cancer

Most Recent Events

  • 30 May 2017 Trastuzumab biosimilar - DM Bio is available for licensing in World (excluding Europe, Latin America, the Commonwealth of Independent States, South Korea and Japan) -
  • 30 May 2017 DM Bio plans a phase III trial for Breast Cancer in Europe (Dong-A Socio pipeline, May 2017)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Breast-cancer in South Korea (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top